The Non-Malignant Channel is supported with funding from Agios (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

EHA 2022 | The safety and efficacy of parsaclisib in autoimmune hemolytic anemia

Name: The safety and efficacy of parsaclisib in autoimmune hemolytic anemia
Uploaded: 2022-06-10T00:00:00Z
Duration: 1 min 42 s
Description: Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, briefly discusses the results of a study evaluating the safety and efficacy of parsaclisib for the treatment of warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Ulrich Jäger • 10 Jun 2022

EHA 2022

Anemias Autoimmune Hemolytic Anemia Cold Agglutinin Disease Non-Malignant Parsaclisib

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, briefly discusses the results of a study evaluating the safety and efficacy of parsaclisib for the treatment of warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.